Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016
"Transthyretin
(ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Directs, Transthyretin (ATTR or Prealbumin or TBPA or TTR) -
Pipeline Review, H2 2016, provides in depth analysis on Transthyretin
(ATTR or Prealbumin or TBPA or TTR) targeted pipeline therapeutics.
The
report provides comprehensive information on the Transthyretin (ATTR
or Prealbumin or TBPA or TTR) ,
targeted
therapeutics, complete with analysis by indications, stage of
development, mechanism of action (MoA), route of administration (RoA)
and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally,
the report provides an overview of key players involved in
Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted
therapeutics development and features dormant and discontinued
projects.
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage.
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
-
The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR)
targeted therapeutics under development by companies and
universities/research institutes based on information derived from
company and industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Transthyretin (ATTR or
Prealbumin or TBPA or TTR) targeted therapeutics and enlists all
their major and minor projects
-
The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR)
targeted therapeutics based on mechanism of action (MoA), route of
administration (RoA) and molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news and deals related to Transthyretin
(ATTR or Prealbumin or TBPA or TTR) targeted therapeutics
Reasons
to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
-
Identify the use of drugs for target identification and drug
repurposing
Comments
Post a Comment